Anzeige
Mehr »
Login
Freitag, 29.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 936718 | ISIN: US30161Q1040 | Ticker-Symbol: EX9
Tradegate
28.03.24
16:46 Uhr
22,240 Euro
+0,270
+1,23 %
1-Jahres-Chart
EXELIXIS INC Chart 1 Jahr
5-Tage-Chart
EXELIXIS INC 5-Tage-Chart
RealtimeGeldBriefZeit
21,73022,27028.03.
21,58022,36028.03.

Aktuelle News zur EXELIXIS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiExelixis director Garber Alan M sells shares worth over $460k4
07.02.Exelixis (EXEL) Q4 Earnings Beat on Lower R&D Spend, Sales Miss28
07.02.Exelixis Inc reports results for the quarter ended in December - Earnings Summary8
06.02.EXELIXIS, INC. - 10-K, Annual Report1
06.02.EXELIXIS, INC. - 8-K, Current Report-
06.02.Recap: Exelixis Q4 Earnings4
06.02.Exelixis Non-GAAP EPS of $0.33 beats by $0.02, revenue of $480M beats by $2.08M5
06.02.Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update173ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and fiscal year of 2023, provided an update on progress toward achieving...
► Artikel lesen
05.02.Exelixis Q4 2023 Earnings Preview7
05.02.Earnings Preview For Exelixis3
30.01.Breaking Down Exelixis: 7 Analysts Share Their Views12
26.01.Roche's Tecentriq and Exelixis/Ipsen's Cabometyx shows promise in phase 3 prostate cancer study35
25.01.Cabometyx and Tecentriq stave off prostate cancer progression as Exelixis joins Novartis on FDA wait list19
23.01.Bristol Myers, Exelixis Reveal 4-Year Follow-Up Results From Cancer Treatment Study15
23.01.BMS, Exelixis and Ipsen announce positive four-year results for kidney cancer regimen14
19.01.Exelixis (EXEL) Reports Positive EU Patent Ruling for Cabometyx5
19.01.European Patent Office Upholds Exelixis' Formulation Patent For CABOMETYX Tablets426PETAH TIKVA (dpa-AFX) - Exelixis Inc. (EXEL) said Thursday that it has successfully defended European Patent number EP2593090 (c-MET Modulator Pharmaceutical Compositions) against three opponents...
► Artikel lesen
18.01.Exelixis, Inc.: European Patent Office Rules in Favor of Exelixis on Formulation Patent Covering CABOMETYX (cabozantinib) Tablets311Exelixis, Inc. (Nasdaq: EXEL) today announced it has successfully defended European Patent number EP2593090 (c-MET Modulator Pharmaceutical Compositions) against three opponents, STADA Arzneimittel...
► Artikel lesen
17.01.Exelixis (EXEL) Outperforms on Cabometyx and Pipeline Progress6
12.01.BioInvent Regains Rights to Immuno-Oncology Targets from Exelixis4
Seite:  Weiter >>
53 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1